



OBJECTIVE

Investment Banking & Valuation

Industry Report

Business Services


Diagnostics & Testing

Key Takeaways

Diagnostic & Testing Companies Continue To Maintain Higher Valuations When Compared To The Broader Healthcare Market Despite Recent Market Upticks

- EBITDA multiples for the diagnostics and testing sector (“Diagnostics & Testing”) sector have traded slightly down over the past month (see Chart II) with the current average EBITDA multiple standing at 16.2x (see Table I), a 2% decrease month over month but a 27% increase over the past 12 months and an 8% increase over the past 6 months
- The broader healthcare market has had a 5% EBITDA multiple increase (S&P 500 Healthcare index) while the specialty pharmaceutical and life sciences market has had a 14% increase (S&P Pharma Biotech & Life Sciences index) (see Chart II)
- We expect this increase in valuation for the broader market to be a positive for the sector as more investors will start to take note of the increase and invest in the sector, continuing to improve valuations
- In addition, in July we saw 5 transactions close in the Diagnostics & Testing sector, an increase of 25% compared to the previous month, not seen since April 2023 (see Chart I)

Chart I | Total M&A Volume⁽¹⁾




Source: S&P Capital IQ

(1) Total USA and Canadian corporate and asset majority control transactions in the Diagnostics & Testing sector

(2) Table I for Diagnostics & Testing comparables

Chart II | TEV / EBITDA⁽²⁾



USA & Canada Listed Companies (>\$20M Market Cap.)

Over the past month, the Diagnostics & Testing sector has traded up 2%, outperforming the broader healthcare market's 1% decrease (S&P 500 Healthcare index) and the specialty pharmaceutical and life sciences market's 3% increase (S&P Pharma Biotech & Life Sciences index) (see Chart III)

Chart III | 1-Year Price Performance⁽¹⁾





Chart IV | 1-Year TEV Performance⁽¹⁾



Source: S&P Capital IQ

(1) Table I for Diagnostics & Testing comparables


USA & Canada Listed Companies (>\$20M Market Cap.)

Thermo Fisher Scientific trades at the higher end of the group along with Bio-Rad Laboratories, RadNet, and Bruker, which have an average EBITDA margin >20%, showcasing that investors are currently favoring healthier and more profitable companies (see Chart IV)

Table I | Select Diagnostics & Testing

Company	Share Price 8/31/23	Equity Value	TEV	TEV/			
				Revenue		EBITDA	
				LTM	2023E	LTM	2023E
Thermo Fisher Scientific Inc.	\$557.10	\$217,933	\$248,986	5.7x	5.7x	23.4x	22.3x
Laboratory Corporation of America Holdings	\$208.10	\$18,458	\$22,836	1.5x	1.9x	10.2x	10.7x
Quest Diagnostics Incorporated	\$131.50	\$14,759	\$19,707	2.1x	2.1x	11.3x	10.7x
Bio-Rad Laboratories, Inc.	\$400.20	\$11,572	\$11,232	4.1x	4.0x	21.0x	19.6x
Natera, Inc.	\$58.73	\$6,698	\$6,407	6.9x	6.2x	na	na
Bruker Corporation	\$65.60	\$9,634	\$10,335	3.8x	3.6x	17.8x	17.0x
QuidelOrtho Corporation	\$82.36	\$5,501	\$8,001	2.5x	2.7x	10.2x	9.8x
RadNet, Inc.	\$33.41	\$2,264	\$3,628	2.6x	2.3x	19.3x	16.0x
Veracyte, Inc.	\$26.40	\$1,921	\$1,745	5.3x	5.0x	na	na
NeoGenomics, Inc.	\$15.03	\$1,917	\$2,117	3.8x	3.7x	na	na
Median		\$6,698	\$8,001	3.8x	3.6x	14.5x	13.3x
Mean		\$29,066	\$33,499	3.8x	3.7x	16.2x	15.2x

Chart IV | TEV / EBITDA & TEV



Source: S&P Capital IQ


Majority Control Corporate and Asset Deals in USA & Canada

Strategic Acquirers continue to be the more dominant group of buyers in the market as interest rates continue to increase and push Financial Acquirers who rely on debt to pause acquisitions. These conditions are expected to reverse in the second half of 2023 as credit markets normalize (see Chart VI)

Table II | Select M&A Transactions

(\$ in million)					
Announce Date	Target	Acquiror	TEV	TEV / LTM	
				Revenue	EBITDA
4/18/22	Inform Diagnostics, Inc.	Fulgent Therapeutics LLC	\$170	na	na
4/4/22	AltheaDx, Inc.	Castle Biosciences, Inc.	\$142	na	na
1/18/22	GeneDx, Inc.	Sema4 Holdings Corp.	\$623	5.3x	na
12/23/21	Personal Genome Diagnostics Inc.	Laboratory Corporation of America Holdings	\$580	na	na
8/9/21	CSI Laboratories, Inc.	Fulgent Genetics, Inc.	\$53	na	na
7/1/21	Intrinsic Imaging LLC	WCG Clinical, Inc.	\$92	na	na
6/7/21	MyHealth Partners Inc.	WELL Health Technologies Corp.	\$200	na	na
5/24/21	Myriad RBM, Inc.	Q2 Solutions LLC	\$198	na	na
4/15/21	Chronix Biomedical, Inc.	OncoCyte Corporation	\$26	na	na
4/11/21	Luminex Corporation	DiaSorin S.p.A.	\$1,866	4.3x	19.8x
3/2/21	Resolution Bioscience, Inc.	Agilent Technologies, Inc.	\$695	19.9x	na
1/5/21	BioTheragnostics, Inc.	Hologic, Inc.	\$223	6.8x	na
2/12/20	Paradigm Diagnostics, Inc.	Exact Sciences Corporation	\$40	na	na
1/27/20	Memorial Hermann Diagnostic	Quest Diagnostics Incorporated	\$120	na	na
Median			\$184	6.0x	19.8x
Mean			\$359	9.1x	19.8x

Chart VI | Total Buyer Mix: Financial vs Strategic⁽¹⁾



Source: S&P Capital IQ

(1) Total USA and Canadian corporate and asset majority control transactions in the Diagnostics & Testing sector

About Objective

Investment Banking Practice

About Us

Objective, Investment Banking & Valuation is a leading investment banking and valuation firm serving middle-market companies across five industry practice groups in an effort to maximize our clients' M&A and valuation advisory results. Our team uses a highly engineered, structured process combined with our industry expertise designed to consistently achieve maximum results.

Industries of Focus

- Business Services
- Consumer
- Healthcare & life Sciences
- Manufacturing & Distribution
- Technology

500+ M&A Transactions Completed*


Has been acquired by

Sell-Side Advisor to StudyKIK


Has been acquired by

a portfolio company of 
Sell-Side Advisor to Bell Canyon Consulting




Has sold assets to

Financial Advisor to MabVax Therapeutics Holdings, Inc.

Undisclosed Healthcare Technology Company
Has been acquired by
Undisclosed San Francisco Based Private Equity Firm
Sell-Side Advisor to the Undisclosed Healthcare Technology Company

Undisclosed Leading Drug Treatments and Diagnostics Company
Strategic Alternatives Advisor to the Undisclosed Company

Undisclosed Leading Contract Research Organization
Sell-Side Advisor to the Undisclosed Contract Research Organization


Has been acquired by

Sell-side Advisor to Supreme Optimization


Has sold its clinical research site operations to

Sell-Side Advisor to Rocky Mountain Movement Disorders Center

Award & Recognition	Forum	Year	Type
Best Investment Bank & Valuation Firm – USA	Acquisition International	2022	Winner
Technology Deal of The Year (Between \$10MM - \$50MM)	M&A Advisor 21st Annual M&A Awards	2022	Finalist
Industrials Deal of The Year (Between \$50MM - \$100MM)	M&A Advisor 21st Annual M&A Awards	2022	Finalist
Private Equity Deal of The Year (Between \$50MM - \$100MM)	M&A Advisor 21st Annual M&A Awards	2022	Finalist
Boutique Investment Banking Firm of the Year	M&A Advisor 20th Annual M&A Awards	2021	Finalist
Best Investment Banking & Valuation Firm - California	Acquisitional International	2021	Winner



About Objective

Business Services Overview

Objective, Investment Banking & Valuation's Business Services practice is widely recognized for its exceptional capabilities in leveraging deep sector expertise and crafting compelling narratives that capture the essence of every company. Our team of highly dedicated and tenacious M&A professionals boasts extensive senior-level relationships with prominent strategic and financial buyers in the professional and technology-related services industries, as well as large public and private enterprises.

With a wealth of experience garnered over many years in both sell-side and buy-side engagements involving business services companies, we provide our clients with invaluable and transparent guidance that empowers them to realize their strategic and financial objectives.

Dedicated
Industry
Knowledge &
Expertise



Thank you!

We are available to assist with your M&A or Valuation advisory needs when you need us. Feel free to call with M&A questions for your specific engagement, or to receive general market insight.



Channing Hamlet*
Managing Director, Business Services
Practice Leader
(310) 570-2721
channing.hamlet@objectivecp.com
[LinkedIn](#)



Cody McPherson
Vice President
(604) 816-1010
cody.mcpherson@objectivecp.com
[LinkedIn](#)



Kai Duncan*
Associate
(321) 427-9450
kai.duncan@objectivecp.com
[LinkedIn](#)

*Registered Representative Of And Securities Products offered through BA Securities LLC